MAPT and Alzheimer disease: Cerebrolysin® is a peptidergic preparation showing clinical efficacy in AD [2, 33, 34], and the ability of reducing Aβ [35–39], tau [40–42], and synaptic pathology [35, 36] in several experimental models.